PatientsVille.com Logo

GASTROINTESTINAL HAEMORRHAGE and Abilify

PatientsVille

GASTROINTESTINAL HAEMORRHAGE Symptoms and Causes

Your digestive or gastrointestinal (GI) tract includes the esophagus, stomach, small intestine, large intestine or colon, rectum, and anus. Bleeding can come from any of these areas. The amount of bleeding can be so small that only a lab test can find it.

Signs of bleeding in the digestive tract depend where it is and how much bleeding there is.

Signs of bleeding in the upper digestive tract include

  • Bright red blood in vomit
  • Vomit that looks like coffee grounds
  • Black or tarry stool
  • Dark blood mixed with stool

Signs of bleeding in the lower digestive tract include

  • Black or tarry stool
  • Dark blood mixed with stool
  • Stool mixed or coated with bright red blood

GI bleeding is not a disease, but a symptom of a disease. There are many possible causes of GI bleeding, including hemorrhoids, peptic ulcers, tears or inflammation in the esophagus, diverticulosis and diverticulitis, ulcerative colitis and Crohn's disease, colonic polyps, or cancer in the colon, stomach or esophagus.

The test used most often to look for the cause of GI bleeding is called endoscopy. It uses a flexible instrument inserted through the mouth or rectum to view the inside of the GI tract. A type of endoscopy called colonoscopy looks at the large intestine.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for GASTROINTESTINAL HAEMORRHAGE

GASTROINTESTINAL HAEMORRHAGE treatment research studies

Abilify clinical trials, surveys and public health registries


Find Drug Side Effect reports



Abilify Side Effects

Weight Increased (762)
Tremor (544)
Tardive Dyskinesia (527)
Insomnia (486)
Pregnancy (435)
Dyskinesia (400)
Dizziness (324)
Somnolence (323)
Nausea (313)
Restlessness (308)
Headache (296)
Fatigue (289)
Psychotic Disorder (287)
Akathisia (286)
Anxiety (281)
Agitation (257)
Vomiting (254)
Convulsion (243)
Delusion (233)
Blood Glucose Increased (228)
Depression (192)
Dystonia (189)
Feeling Abnormal (188)
Vision Blurred (185)
Suicidal Ideation (179)
Death (178)
Mania (178)
Hallucination (176)
Aggression (174)
Neuroleptic Malignant Syndrome (169)
Fall (169)
Confusional State (167)
Weight Decreased (150)
Extrapyramidal Disorder (140)
Dyspnoea (136)
Hallucination, Auditory (136)
Schizophrenia (135)
Gait Disturbance (135)
Abnormal Behaviour (135)
Muscle Spasms (133)
Suicide Attempt (131)
Loss Of Consciousness (128)
Hyperhidrosis (125)
Musculoskeletal Stiffness (123)
Dysphagia (123)
Asthenia (121)
Blood Creatine Phosphokinase Increased (110)
Oedema Peripheral (109)
Completed Suicide (108)
Irritability (105)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

dystonia...on the right hand

Abilify for BiPolar Disorder, how does it work for you?

Abilify lifts the cloud of depression for me But - the sweating is profuse -- just dripping if I do any kind of movement

Abilify, lost everything, could'nt stop gambling until I got off of it.

Abilify, side effects ruined my life. I have compulsive bahavior, I gambled I lost everything. I am looking for a good Lawyer. (409) 548-0460.

As human experience is limited, administration of aripiprazole should be used in pregnancy only if the potential benefit to the mother outweighs the potential risk to the foetus.

Can it cause constipation? My lil was had been bad

Can't sleep any more than 3 to 4 hours at a time anyone else with that problem?

Developed bruxism after starting abilify and lithium

Did not know what was going on, panic attacks yesterday. muscle cramping and tremor, sleeplessness, its all here, going off of this. very scary

Actuallly the risk of a gastrointestinal bleeding is increased with Pradaxa compared to Warfarin, there isalso an interaction withVerapamil leading to higher plama levels of Pradaxa.

Gastrointestinal. Severe pain starting in middle of chest and wrapping around to middle of back. Tests showed inflamation in stomach and I am now on a bland diet indefinately. Also had trouble swallowing pills and food.&

Hi! Some years ago I took nexium for v. severe gerd, with haemorrhage. From the time I started it, suddenly my gastric system was totally upset, where it hadn't previously. Because I wasn't digesting properly, my immune system was affected, and hav

I am currently involve in a case study about hypercholesterilemia, our patient was given Niacin and Cholestyramine resin(Questran) it was stop because the patient cannot tolerate the flushing and gastrointestinal effects bought by this drugs and repl

I had funny gastrointestinal feelings. Almost as if balloons were popping in my stomach. I had the urge to stool but only the flatulence sound---no stools. I always felt so 'empty' even though I was eating regularly. I stopped at three days I couldn'

I have had Aclasta infusions twice now. On both occasions I experienced gastrointestinal symptoms but three weeks later. One time, it was very acute, right lower quadrant pain, and this year it has been cramps and diarrhea. First time, I felt unwell

I received a dose on May 12 and May 13, 2010 that Friday on May16 i got a really violent headache. By Saturday, I ended up with terrible sweating, fatigue, gastrointestinal problems. On Sunday more of the same. Monday st

I take Vastarel MR once a day. Tired, gastrointestinal increase

I was diagnosed with diabetes 2 years ago and have been taking one diabex xr tablet per day with dinner . Since then I have had gastrointestinal problems which only ease with gastro stop tabletswhen needed. I am frightened to goan

I was diagnosed with diabetes 2 years ago. I take one tablet a day with dinner, Since taking diabex I have cramps, and diarrea and gastrointestinal problems . My life is becoming a series of toilet seeking on journeys and I hate travelling. Could thi

GASTROINTESTINAL HAEMORRHAGE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Aripiprazole 6-week group;   Drug: Aripiprazole 8-week group
Outcome Measures: Quality of Life Scale (QOLS);   Montgomery-Åsberg Depression Rating Scale
2 Unknown  Aripiprazole and Topiramate on Free-Choice Alcohol Use
Condition: Alcohol Dependence
Interventions: Drug: Double Placebo;   Drug: Aripiprazole 15, placebo;   Drug: Aripiprazole 7.5, Placebo;   Drug: Topiramate 100, Placebo;   Drug: Topiramate 200, Placebo;   Drug: Topiramate 100, Aripiprazole 15;   Drug: Topiramate 100, Aripiprazole 7.5;   Drug: Topiramate 100, Aripiprazole 15mg;   Drug: Topiramate 200, Aripiprazole 7.5mg;   Drug: Topiramate 200, Aripiprazole 15
Outcome Measures: Number of alcoholic drinks consumed in a laboratory setting;   Safety and tolerability of the medications singly and in combination, compared to placebo;   Drinks consumed during the medication titration period
3 Recruiting Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia
Condition: Hyperprolactinemia
Interventions: Drug: Aripiprazole;   Drug: Placebo
Outcome Measures: To determine if adjunct aripiprazole will resolve or improve prolactin related hormonal side effects (amenorrhea, oligomenorrhea, galactorrhea).;   To test whether adjunctive aripiprazole will improve quality/perceived quality of life.;   To identify if adjunct aripiprazole will improve bone turnover as measured by assays of osteoblastic and osteoclastic activity.;   To examine side effects associated with adjunctive aripiprazole versus placebo and conduct a cost analysis of adjunctive aripiprazole use.;   To evaluate the mediator effects of estrogen, progesterone, prolactin effects on quality of life, bone turnover and sexual functioning.
4 Unknown  The New Strategy for Pharmacological Treatment in People With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Rispridoen and Aripiprazole;   Drug: Risperidne;   Drug: Abilify
Outcome Measures: SANS(Scale for the Assessment of Negative Symptoms);   SARS(Simpson-Angus Rating Scale);   Drug Attitude Inventory;   Side effect checklist
5 Recruiting Study to Evaluate the Efficacy and Safety of Aripiprazole
Condition: Autism
Intervention: Drug: Aripiprazole
Outcome Measures: irritability subscale of the aberrant behavior checklist;   Change from baseline in ABC-subscale of lethargy/social withdrawal, stereotypic behavior, hyperactivity, inappropriate speech;   Change of CGI-S, CGI-I from baseline;   Change of Behavioral problems from baseline;   Change of Adaptive Skills from baseline;   Change of Parental stress from baseline
6 Recruiting Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients
Condition: Bipolar I Disorder
Interventions: Drug: Intramuscular (IM) Depot Aripiprazole;   Drug: Intramuscular (IM) Depot Placebo
Outcome Measures: Time from randomization to recurrence of any mood episode during Double-Bind Placebo Controlled phase;   Proportion of subjects meeting criteria for recurrence of any mood episode(manic, mixed, depressive);   Mean change from randomization to endpoint in the CGI-BP-S (mania) score;   Time from randomization to recurrence defined by hospitalization for a mood episode.
7 Unknown  Neuroimaging Of Treatment Effects in Treatment-Resistant Depression
Condition: Major Depressive Disorder
Intervention: Drug: escitalopram and adjunctive aripiprazole and placebo
Outcome Measures: Use of PET and fMRI to demonstrate the differential pattern of dopaminergic activity, dopamine receptor binding in the putamen and caudate and correlation these findings to MADRS in MDD subjects treated with escitalopram and aripiprazole.;   Correlation of D2binding before and after adjunctive aripiprazole with emergence of extrapyramidal symptoms and akathisia.
8 Recruiting Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Aripiprazole and aripiprazole once-monthly;   Drug: Paliperidone and paliperidone palmitate
Outcome Measures: Mean change from Baseline in quality of life;   Investigator's assessment of overall effectiveness;   Mean change from Baseline in clinical global impression;   Mean change from Baseline in quality of life using QLS;   Mean change from Baseline in subjective well-being using SWN-S;   Mean change from Baseline in tolerability and quality of life using TooL;   Safety and tolerability;   Risk of suicidality
9 Recruiting Aripiprazole and Prolactin Study
Condition: Hyperprolactinemia
Intervention: Drug: Aripiprazole
Outcome Measures: Normalization or reduction in prolactin sufficient to restore gonadal function;   Normalization or improvement in bone mineral density
10 Recruiting A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole
Outcome Measures: Adverse events;   Positive and Negative Syndrome Scale (PANSS);   Clinical golobal impression (CGI);   Children's Global Assessment Scale (CGAS)
11 Unknown  Aripiprazole Augmentation Therapy in Treatment-resistant Depression
Condition: Therapy-resistant Depression
Intervention: Drug: Aripiprazole
Outcome Measure: rate of response as defined by a more or equal 50 % reduction of baseline HAM-D (Hamilton Depression Rating scale)
12 Recruiting Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole
Outcome Measures: Prolactin level;   PANSS (positive and negative syndrome scale) score
13 Recruiting A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Aripiprazole Low (2 mg/day);   Drug: Aripiprazole Mid (6 - 12 mg/day);   Drug: Aripiprazole High (24 - 30 mg/day)
Outcome Measures: Positive and Negative Syndrome Scale (PANSS) total sore;   PANSS score;   Clinical Global Impression (CGI);   Children's Global Assessment Scale (CGAS);   Adverse events;   Electrocardiogram
14 Unknown  Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole
Conditions: Schizophrenia;   Sensory Gating
Intervention: Drug: Aripiprzole
Outcome Measure: MEG/EEG and MRI data will be compared with the results of a neuropsych battery and symptom rating scales prior to initiation with aripiprazole and after subject has been on a stable dose of aripiprazole for three month.
15 Unknown  Aripiprazole and Resistant Postpartum Depression
Condition: Postpartum Depression
Intervention: Drug: aripiprazole
Outcome Measures: Montgomery Asberg Depression Rating Scale;   Udvalg for Kliniske Undersogelser Scale
16 Recruiting Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
Condition: Bipolar I
Intervention: Drug: Aripiprazole
Outcome Measures: Number and percentage of subjects with adverse events;   Injection Site Pain measured by the Visual Analog Scale (VAS);   Number and percentage of subjects with clinically significant abnormal laboratory test results, vitals, ECGs;   Extrapyramidal Symptoms (EPS) will be assessed by change from baseline on Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale (SAS), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS used in Japan), and Barnes Akathisia Rating Scale (BARS);   Percentage of subjects who remain stable at endpoint
17 Unknown  Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism
Condition: Autistic Disorder
Interventions: Drug: Aripiprazole;   Drug: Placebo;   Drug: D-cycloserine;   Other: fMRI
Outcome Measures: Aberrant Behavior Checklist (ABC) Irritability Subscale;   Clinical Global Impression (CGI) Scale;   ABC Subscales;   Vineland Maladaptive Behavior Subscales;   A modified version of the Compulsion Subscale of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS);   Autism Diagnostic Observation Schedule (ADOS);   Social Reciprocity Scale (SRS)
18 Recruiting Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
Condition: Autistic Disorder
Interventions: Drug: Aripiprazole;   Drug: Risperidone
Outcome Measure: To identify phenotypic and genetic traits that predict response to aripiprazole and risperidone in Autistic Disorder
19 Recruiting Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study
Conditions: Bipolar Disorder;   Depressive Episode
Interventions: Drug: Low dose Adjunctive Aripiprazole;   Drug: placebo
Outcome Measure: Response rate
20 Recruiting A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
Conditions: Schizophrenia;   Cocaine Dependence
Interventions: Drug: Aripiprazole;   Drug: Perphenazine
Outcome Measures: The proportion of negative urine drug screen results will be significantly greater in the subjects treated with aripiprazole than in those treated with perphenazine.;   The mean total self-report cocaine use days will be significantly fewer in subjects treated with aripiprazole than in those treated with perphenazine.;   The mean cocaine craving scores will be lower in subjects treated with aripiprazole than in those treated with perphenazine.